# Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome

> **NCT05298475** · PHASE4 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** Statin
- **DRUG:** PCSK9 inhibitor
- **DRUG:** PCSK9 inhibitor

## Key facts

- **NCT ID:** NCT05298475
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-01
- **Primary completion:** 2023-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05298475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05298475, "Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05298475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*